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The activation of CD4+ T cells is controlled via three distinct signals: TCR 
recognition of the peptide:MHCII complex, coactivation via ligands and receptors 
expressed on antigen-presenting cells and the T cell, and Signal 3 cytokine signaling. It is 
this third signal that leads to initial differentiation into the multiple T helper subsets such 
as Th1, Th2, Th17, and Treg. While the role of Signal 3 cytokines is well-defined in 
programming differentiation after activation of naïve T cells, their effects on memory CD4+ 
T cell responses have not been extensively studied. Here we show that interruption of 
cytokine signaling during secondary CD4+ T cell responses alters their effector function. 
These effects are independent of TCR affinity for antigen, demonstrating a critical role for 
appropriate cytokine signaling in the successful production of robust secondary CD4+ T 
cell responses. 
During secondary challenge with Listeria monocytogenes, CD4+ T cell responses 
are differentially regulated by Type I IFN (IFN-I) and IL-12. Effector function is depressed 
in the presence of IFN-I signaling, while IL-12 promotes the differentiation of highly 
functional secondary effector cells. Additionally, the mechanisms of regulation by both 
cytokines may intersect, as IFN-I inhibits the production of IL-12 as well as IFNγ, a critical 
cytokine for Th1 responses and bacterial clearance. Expansion kinetics are also controlled 
via these cytokines, with IL-12 promoting robust initial expansion and IFN-I inhibiting 
expansion but required for limiting contraction during memory formation. 
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Importantly, memory CD4+ T cells alone are able to mediate significant protection 
from heterologous secondary challenge with Listeria. This protection is entirely dependent 
upon TNF, as neutralization of this cytokine results in complete loss of CD4+ memory T 
cell-mediated protection. Surprisingly, IFNγ is not required for protection mediated by 
secondary effector CD4+ T cells in this setting, though it is required for protection from 
primary challenge with Listeria. Rather, TNF-dependent differentiation of secondary 
effector Th1 cells drives increased classical macrophage activation, leading to more rapid 
bacterial clearance. Together, we demonstrate an important role for cytokine signaling in 
determining the strength of the secondary response of CD4+ T cells, which can directly 
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Primary T Cell Responses 
Upon recognition of cognate antigen by the T cell receptor (TCR), T cells undergo 
rapid activation, differentiation, and expansion into effector cells. These activated T cells 
can then perform a variety of functions to facilitate pathogen clearance, such as direct cell 
killing in the case of CD8+ killer T cells (CTLs) or coordination of immune responses of 
other cell types in the case of CD4+ helper T cells (1–4). CD4+ T cells can differentiate into 
a variety of subsets with distinct functionalities including T helper 1 (Th1), Th2, Th17, and 
T regulatory cells (Tregs). Th1 cells produce IFNγ, IL-2, and TNF and are induced by 
intracellular pathogens such as viruses and intracellular bacteria. Th2 cells produce IL-4 
and IL-5 and are induced by extracellular parasites and during allergic reactions. Th17 cells 
are primarily found at mucosal surfaces in response to extracellular bacteria and fungi and 
produce IL-17 and IL-21. Tregs are induced in response to inflammation to prevent 
uncontrolled inflammation and resolve immune responses via production of IL-10 (1). 
Importantly, CD8+ T cells require CD4+ T cells, particularly Th1 cells, in order to produce 
optimal primary responses that result in a memory population capable of producing a robust 
secondary effector response (5, 6).  
During an acute infection antigen presenting cells (APCs) process and present 
antigen to CD8+ and CD4+ T cells via the major histocompatibility complex (MHC) I or 
II, respectively. Cells with TCR specificity to the presented antigen are activated and 
expand upon recognition of peptide presented by MHC (peptide:MHC), producing a 
polyclonal population of T cells with varying affinities for antigen. After pathogen 
clearance, the population size of these primary effector cells decreases by up to 95%, 
leaving a small population of long-lived memory cells that are able to rapidly respond to 
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subsequent antigen encounter (7, 8). The memory population responds more rapidly and 
robustly to secondary challenge with the same pathogen, resulting in faster clearance of 
successive infections. However, the processes that regulate primary immune responses 
may be distinct from those that regulate subsequent rechallenges.  
Signals of T Cell Activation 
During a primary immune response, T cells are activated via three distinct signals. 
Signal 1 is the initial TCR recognition of peptide:MHC on the surface of antigen presenting 
cells (9–11). Signal 2 is comprised of costimulatory molecules on the surfaces of both the 
APC and the T cell, such as CD28 on naïve T cells binding to CD80/86 (B7-1/2) on the 
surface of APCs. Signal 3 is comprised of inflammatory molecules known as cytokines, 
typically produced by cells of the innate immune system, which help to differentiate and 
activate both CTLs and CD4+ helper cells. For example, CTL activation requires Th1 help 
via production of cytokines such as IFNγ and IL-2. Activation of CD4+ T helper cells is 
complex, as specific cytokine signaling leads to lineage commitment into helper subsets 
with defined function (e.g., IL-12 promotes Th1 differentiation, IL-4 promotes Th2, etc.) 
(12). While Signal 3 cytokines are well studied in the context of naïve T helper cell 
activation and differentiation, the role of cytokine signaling in secondary effector responses 
is poorly understood. The production of Signal 3 cytokines is dramatically altered when 
comparing primary and secondary T cell responses, as contribution of memory responses 
alters the cytokine milieu early in a secondary response. Our work and that of other groups 
suggests that activation of secondary effector T cells may have different Signal 3 
requirements than that of primary effectors (8, 13, 14).  
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Signal 3 Cytokines for T Cell Activation 
Type I IFNs (IFN-I), comprised of 14 IFN-α genes and one IFN-β in mice (15), are 
key Signal 3 cytokines. While IFN-I signaling is required for protection from viral 
infections, loss of IFN-I signaling proves to be protective during some bacterial infections, 
including Listeria monocytogenes (Lm) (16, 17). Significant work has been done to 
determine the role of IFN-I signaling in CD8+ T cell activation in both viral and bacterial 
settings. Interestingly, while there are opposite roles for IFN-I in overall protection from 
viral and bacterial infections, in both settings there is a requirement for IFN-I signaling in 
CD8+ T cell activation (11, 18–20). During the first week of a primary viral infection with 
lymphocytic choriomeningitis virus (LCMV) antigen-specific CD8+ T cells undergo up to 
10,000-fold expansion. Expansion is dependent upon IFN-I signaling, as loss of the IFN-I 
receptor on CD8+ T cells causes an almost complete loss of clonal expansion during 
infection (18). The enhancement of T cell responses only occurs when T cells encounter 
IFN-I during or after T cell priming, as preincubation of T cells with IFN-I leads to 
dampening of their responsiveness (7, 21–23). Additionally, the role of IFN-I appears to 
be primarily in reducing contraction or promoting expansion during the later phase of the 
acute response. Consistent with this, there is no defect observed in the expansion of CD8+ 
T cells for the first few days of a viral infection in the absence of IFN-I signaling, but there 
is a defect observed in the later phase of the primary immune response (24). Others have 
shown that IFN-I induces resistance to apoptosis, including through upregulation of the 
antiapoptotic protein Bcl-2 and sustained expression of IL-2Rα on T cells (20, 25). The 
role of IFN-I signaling to T cells is dependent upon the pathogen, as IFN-I is required for 
expansion of CD8+ T cells during LCMV infection, but loss of direct IFN-I signaling alone 
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is not sufficient to reduce CTL numbers during infection with Listeria (11). 
Further understanding of the role IFN-I plays in shaping the inflammatory 
environment of different immune responses is required to elucidate the mechanisms by 
which IFN-I signaling mediates protection or susceptibility, as well and how it controls T 
cell responses in different settings. Due to the ubiquitous expression of IFNAR, most cell 
types can be influenced by IFN-I signaling. Dendritic cells (DCs) are a source of IFN-I 
during infection, with plasmacytoid DCs (pDCs) producing IFN-I in response to viral 
infection and conventional DCs producing IFN-I in response to bacteria present in the 
phagosome but not in the cytosol (26, 27). IFN-I signaling is subsequently induced in T 
cells and other cells, particularly macrophages in the case of Lm and other intracellular 
infections. It has been observed that IFN-I signaling can reduce surface expression of the 
type II interferon receptor (IFNγR) on macrophages rapidly after infection (28, 29). 
Macrophages that are refractory to IFNγ signaling are unable to properly upregulate 
proinflammatory signaling pathways and cytokine production, reducing the overall 
inflammatory environment and dampening the protective immune response in the case of 
acute infection. While much of the published literature would suggest an apparently simple 
model wherein IFN-I signaling is detrimental to bacterial clearance and IFNγ signaling is 
beneficial, the situation is not quite so straightforward. Both IFN-I and IFN signal through 
Stat1, causing some signaling redundancies that may have unforeseen implications in long-
term immunity  (30). 
Type II IFN, comprised of only a single IFNγ gene, is well studied in innate and 
adaptive immune responses. As previously mentioned, macrophages require IFNγ 
responsiveness to promote protection from bacterial infections. Whole animal knockout of 
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the IFNγR leads to early death by normally sublethal amounts of Lm (31). Cell-specific 
receptor knockouts show that macrophages and CD8+ DCs are particularly responsible for 
increased susceptibility when lacking the IFNγR during a primary response to Lm (32–34). 
This is partially due to a reduction of MHCII on macrophages and reduced listericidal 
activity, as well as a loss of the initial burst of IL-12 traditionally provided by CD8+ DCs. 
In addition to roles in innate cell function, IFNγ has a very important pathogen-dependent 
role in the development of T cell responses. In general, Th1 cells are required for formation 
of optimal CD8+ T cell responses, with reduced numbers and functional capacity for CD8+ 
memory T cells generated in the absence of CD4+ T cells (5, 35). IFNγ is centrally 
important for this T cell help, as Th1 cells produce significant levels of IFNγ, and a lack of 
CD4+ T cell help during CTL responses results in reduced IFNγ production by CD8+ T 
cells. Others have also observed that the secondary response to a Listeria infection requires 
IFNγ, and increased systemic levels of this cytokine provide increased protection during 
the secondary response (36). However, we observe that this is not always the case, as we 
show that memory CD4+ T cell-mediated protection from Listeria infection is not altered 
by the loss of IFNγ through cytokine neutralization (Chapter 3). While IFNγ generally 
promotes protection and clearance, exceptions to this rule exist (37). Taken together, we 
can conclude that the interferon family of cytokines has a complex role in promoting 
immunity that is dependent on the infectious and inflammatory environment. 
Interferons alone are not responsible for regulating protective immunity. Much of 
the work that has examined IFN-I as a Signal 3 cytokine has also shown that IL-12 is 
important in defining the dominant cytokine profile of the immune response. IFN-I has a 
regulatory effect on the production of IL-12, and Ifnar-/- mice infected with Lm show much 
7 
higher systemic levels of IL-12 than their WT counterparts (19). Both IFN-I and IL-12 
have important roles in the production of effective CD8+ T cell effector cells. Specifically, 
IL-12 is required in addition to IFN-I during the later phase of the adaptive immune 
response to prolong expression of the IL-2Rα and promote sustained division (11, 20). 
During Listeria infection, IL-12 signaling is required to drive the differentiation of short-
lived effector cells (SLECs), a critical component of protective immunity to this pathogen. 
T cells lacking the IL-12 receptor showed no defect in SLEC differentiation in the setting 
of a viral infection, indicating that cell fate is determined independent of IL-12 signaling 
in an antiviral response (10). While the immune response to a viral infection is dominated 
by IFN-I signaling, IL-12 is more critical for protective responses to bacterial pathogens, 
as evidenced by normal CD8+ T cell expansion and function in response to lymphocytic 
choriomeningitis virus (LCMV) and vaccinia virus (VV) when these cells lack the IL-12 
receptor. This is not as simple as differences caused by viral and bacterial infections, as 
vesicular stomatitis virus (VSV) infection of mice with IL-12RKO CD8+ T cells induces 
less robust antigen-specific T cell responses in the absence of both IFN-I and IL-12 
signaling, indicating both cooperative and distinct roles for these signaling pathways in 
modulating T cell responses (11). 
Production of IL-12 can be induced in three ways. First, IL-12 can be produced in 
a T cell-independent manner through direct stimulation of innate cells such as macrophages 
and DCs. Second, T cell-dependent production of IL-12 is initiated when CD40 on the 
surface of macrophages or DCs binds CD40L expressed on T cells (38). Finally, there is a 
third method of IL-12 induction that involves macrophages recognizing components of the 
extracellular matrix and inducing production, though this is a much less important source 
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of IL-12 in the setting of an acute infection (39). IL-12 is known to induce a number of 
important proinflammatory cytokines, such as IFNγ, tumor necrosis factor (TNF), IL-6 and 
IL-1β (36, 40, 41). Previous work implies that protection during a secondary infection is 
IL-12 independent, as IL-12 depletion during secondary challenge with Listeria exhibited 
no increase in bacterial burden (41, 42). There appears to be a feedback loop involving 
IFN-I, IFNγ, and IL-12 signaling, particularly in a primary Listeria infection, but the role 
of these cytokines specifically concerning CD4+ T cells and secondary responses is not 
completely understood.  
While much of the focus on the impact of Signal 3 cytokine signaling to T cells has 
focused on the aforementioned interferons and IL-12, there are additional cytokines that 
may play important roles in T cell-mediated immunity. TNF is a pleotropic cytokine that 
can lead to activation-induced cell death (AICD) and thereby control the magnitude of the 
T cell response (43). In addition to the death domain, TNF-activated NF-κB signaling 
induces a variety of proinflammatory cytokines. Similarly, IFNγ signaling through Stat1 
can also be increased by the presence of TNF, resulting in stronger IFNγ signaling (44). 
Importantly, Listeria infection of TNFR-/- mice resulted in an IL-12 deficiency, indicating 
an important role for TNF in the induction of IL-12 and downstream cytokine signaling 
(45). Though there is significant literature studying the role of TNF, the pleotropic nature 
of this cytokine makes it difficult to fully determine the specific role of TNF signaling in 
T cell-mediated protection. More targeted study of the role of this cytokine and its various 
signaling pathways will elucidate individual aspects of the function of TNF. 
Induction of IL-6 is one hallmark of Listeria infection (46). Classical signaling 
through the IL-6 pathway occurs via the IL-6 receptor that is present on the surface of 
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hepatocytes and some leukocytes. More ubiquitously, IL-6 is also able to bind a soluble 
version of the IL-6Rα, which can subsequently bind and dimerize with the ubiquitously 
expressed gp130 chain of the receptor (47). Termed trans-signaling, this pathway is 
dispensable for normal immunity, but loss of classical signaling causes impaired control of 
infection and large changes to the overall inflammatory environment. IL-6 is induced by 
both IFNγ and TNF, and overexpression of IL-6 increases protection from primary Listeria 
infection (48, 49). Production of IL-6 can occur in both T cell-dependent and -independent 
manners, with macrophages being implicated as a major source of the cytokine (50, 51). 
Interestingly, IL-6 has differential effects on naïve and memory CD4+ T cells, with a 
requirement during primary responses for the formation of productive memory populations 
but proving expendable during the secondary response (52). However, loss of protection 
due to IL-6 knockout during a primary infection has been shown to be reversible through 
administration of recombinant IL-12, indicating that these cytokines signal through the 
same or similar pathways to mediate protection (53). As with all examples reviewed here, 
it is likely that these are not hard and fast rules for every type of infection, but rather will 
change based on the inflammatory environment formed by individual pathogens. Rather, 
what should be noted is the relationship between all of the cytokines enumerated so far, 
and the direct and sometimes opposing roles they have been shown to play in T cell immune 
responses. 
All of the aforementioned cytokines are broadly inflammatory, though some, such 
as TNF, have been shown to perform immunoregulatory functions as well. Importantly, all 
inflammatory immune responses also induce expression of immune dampening factors to 
allow for proper resolution of inflammation after pathogen clearance. IL-10 is an 
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antiinflammatory cytokine produced by Tregs and monocytes that downregulates the 
expression of costimulatory molecules on macrophages as well as the production of Th1 
cytokines (54). It is therefore unsurprising that treatment with IL-10 neutralizing antibody 
leads to increased resistance from infection with Listeria. However, without IL-10 
signaling, complete clearance may be inhibited, likely due to anergy and/or death of T cells 
caused by prolonged exposure to high levels of inflammation (55). Consistent with this, 
memory cells generated in il10-/- mice were lower in number and protective capacity. As 
with IL-6, signaling from IL-10 to T cells was only required during primary memory 
formation, and  memory cells generated in a WT host and subsequently transferred to an 
il10-/-  host could provide protection from a subsequent challenge (56). As the evidence 
presented here for Signal 3 cytokines demonstrates, requirements for individual cytokines 
are dependent on a number of factors, including type of pathogen, inflammatory 
environment, and phase of the response. It is one of the goals of our lab to determine the 
specific roles of these and other cytokines in the induction of both primary and secondary 
CD4+ T cell responses. 
 
Models for Study of Secondary Responses 
The study of secondary responses in individual cell types is challenging, as 
secondary challenge of a host results in stimulation of all specific memory cells, including 
CD8+ T cells, CD4+ T cells, B cells, and even some innate memory (57). Unfortunately, 
this makes it impossible to determine the contribution of individual cell types in protection 
from secondary challenge. Many groups, including ours, have utilized an adoptive transfer 
model wherein specific cell subsets are isolated and then transferred to a secondary, naïve 
host (8, 10, 19). It is then possible to study antigen-specific secondary responses in an 
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individual cell type, as we can control which memory populations are present. We have 
utilized adoptive transfer of SMARTA T cells, a monoclonal TCR transgenic line with 
specificity to the MHCII-restricted GP61-80 epitope of LCMV. This approach has allowed 
us to study TCR-independent mechanisms of T cell activation due to the presence of a 
single TCR with a specific affinity for antigen (58). However, the adoptive transfer model 
may fail to accurately replicate an actual secondary challenge due to high numbers of 
antigen-specific cells involved in the transfer. For this reason, we also utilized a prime-
boost model of rechallenge in the same host. In our prime-boost model, termed 
heterologous rechallenge, animals are first infected with LCMV. After memory formation 
(>30 days), animals are given a secondary challenge with Listeria expressing the MHCII-
restricted GP61-80 epitope of LCMV (Lm-gp61) (2, 8). Using this method, we can 
specifically restimulate memory CD4+ T cells produced by the primary LCMV infection 
without rapid clearance mediated by CD8+ memory T cells or antibodies. More 
importantly, this allows us to study the protective role of endogenous CD4+ T cell memory 
without the confounding effects of cell transfer. The following dissertation utilizes both 
models, often in conjunction, to study the role of the inflammatory environment on 
secondary effector CD4+ T cell responses and to assess the specific inflammatory 
cytokines involved. 
Clinical Relevance of CD4+ T Cell Memory 
For the development of vaccines and immunotherapuetics, understanding of the 
mechanisms that regulate immune responses is invaluable for producing treatments that 
appropriately manipulate the immune system to the benefit of the patient. This is most 
commonly apparent in the use of vaccines and adjuvants. Vaccinations are performed with 
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the purpose of producing long-lived immune memory to prevent severe infection from 
encounter of the pathogen (59). Adjuvants are provided in conjunction to stimulate the 
innate immune system and allow for a complete T cell response to the vaccine antigen. 
Successful vaccines result in limited bystander activation, targeted stimulation of antigen-
specific cells, and subsequent formation of long-lived memory cells (60). Single 
vaccinations are not always sufficient to form immunity for the life of the individual, and 
both homologous and heterologous prime-boost strategies have been used in vaccine 
therapies. Differences in CD4+ and CD8+ T cell activation are one reason for the use of 
prime-boost, as in certain cases low doses of antigen are sufficient to stimulate one cell 
type and not the other, while high doses can impede memory formation in some cases (61). 
Heterologous prime-boost vaccination may be sufficient to engage appropriate responses 
from both CD4+ T cells and CTLs and result in long-lasting immune memory. Due to the 
vast amount of literature indicating the important role for cytokine signaling throughout 
the entire T cell response, understanding the signaling molecules that are produced during 
vaccination and their roles in T cell responses will allow for the generation of both more 
robust vaccines and potentially new adjuvants. 
 Personalized therapies revolving around the genetic and immune profiles of tumors 
are becoming more common in cancer immunotherapy, wherein clinicians manipulate a 
patient’s own immune system to more robustly fight the cancer based on specific markers 
present in their immune systems and tumors (62). Clinical trials are underway for a variety 
of combination therapies involving oncolytic viruses (Takara), and chimeric antigen 
receptor (CAR)-T cell therapy has also been used to target cancer cells (63). Difficulties 
arise when it comes to manipulating the immune system of a patient with cancer, as CD4+ 
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T cells in particular can have both antitumor and immunosuppressive properties. While 
Th1 cells are beneficial to the immune response against cancer cells, Treg cells dampen the 
immune response and lead to suppression of both CD4+ T cell and CTL responses, allowing 
for tumor immune evasion and growth (64–66). The presence of active tumor infiltrating 
lymphocytes (TILs) in the tumor has been shown to positively correlate to patient outcome 
(62, 67), supporting a therapeutic approach of limiting Treg responses while promoting 
recruitment and antitumor activity of other T cells. Unfortunately, simple transient 
depletion of the CD4+ T cell compartment would likely not be effective, as it would 
eliminate proinflammatory CD4+ T cell help along with Tregs, reducing CTL efficacy. 
Mouse studies show that CD4+ T cell vaccines can cause tumor rejection, so improved 
antitumor vaccines may just be the next step in cancer immunotherapy. In order to one day 
develop therapeutics such as these for use in human subjects, we must first understand the 
mechanisms that produce optimal T cell recall responses. 
 
Summary of Dissertation 
 While a significant amount of T cell research focuses on CD8+ T cell responses, I 
argue that understanding of CD4+ T cells and the mechanisms controlling their responses 
is equally important. This is due to the broadly immunoregulatory and immunostimulatory 
roles of T helper cells, in addition to some more recently discovered direct roles in cell 
killing (68, 69). The following dissertation focuses primarily on secondary effector 
responses of antigen-specific CD4+ T cells. With these and future studies, we hope to 
understand the protective role of memory CD4+ T cells alone and the signaling mechanisms 
that control them.  Understanding differences between primary and secondary effector 
responses, specifically environmental cues that dictate strong secondary responses, will 
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allow for the development of more robust prime-boost vaccinations and 
immunotherapeutics. 
To determine the role of Signal 3 cytokines in reactivation of memory CD4+ T cells, 
we utilized the previously described TCR transgenic, adoptive transfer, and heterologous 
secondary challenge models to study TCR-independent mechanisms of T cell activation. 
In Chapter 2, we examine the role of IL-12 and IFN-I in secondary CD4+ T cell effector 
function during bacterial challenge. We observe a TCR-independent effect on T cell 
functional avidity, a measure of T cell responsiveness to cognate antigen, with IL-12 and 
IFN-I having opposite effects on secondary effector function. Specifically, we note that in 
the presence of IL-12 signaling there are elevated levels of IFNγ and increased functional 
avidity of secondary effector T cells at peak response compared to a primary effector 
population. IFN-I, on the other hand, inhibits circulating IFNγ levels as well as T cell 
functional avidity. IFNγ inhibition by IFN-I may be through direct signaling to IFNAR on 
T cells, as levels were not elevated when all cells except for memory T cells lacked this 
receptor. Otherwise, IFN-I appears to play an indirect role in controlling CD4+ T cell 
function. We observe similar roles for IL-10 signaling and IFN-I signaling, though the 
mechanisms each cytokine uses to impact effector T cell function appear to be different 
due to the downstream cytokines each regulates.  
Other cytokines may also be important for secondary effector Th1 cells, most 
importantly IFNγ and TNF. Previous work by other groups has shown a key role for TNF 
in CD8+ T cell effector responses, and IFNγ is a known important mediator of protection 
from primary infection with Listeria. In Chapter 3, we explore the roles of IFNγ and TNF 
in a secondary Listeria infection where protection is mediated by CD4+ memory T cells. 
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Surprisingly, IFNγ is expendable for memory CD4+ T cell-mediated protection from 
secondary infection, as evidenced by little to no loss of protection when IFNγ is 
neutralized. Rather, TNF appears to be necessary for CD4+ T cell mediated protection, with 
complete loss of protection observed in the absence of TNF signaling. This effect correlates 
with a decrease in classically activated macrophages, particularly macrophages expressing 
IFNγR1. While IFNγ neutralization does not greatly affect protection, expression of its 
receptor appears to be important for macrophages nonetheless, indicating that there is still 
a role for IFNγ signaling in secondary protection mediated by CD4+ T cells. Interestingly, 
in data presented in both Chapters 2 and 3, we observe significant changes in IL-6 
concentrations when we manipulate the cytokine milieu via neutralizing or blocking 
antibodies. This appears to be secondary to the effects on protection, as neutralization of 
IL-6 has no significant effect on CD4+ T cell-mediated protection. Other work has indicated 
a role for IL-6 in primary immune responses, but in our hands there appears to be no 
significant role for IL-6 in secondary immune responses. Overall, the data presented in this 
dissertation describe mechanisms of programming secondary CD4+ T cell responses by 
cytokine signaling in a TCR and possibly antigen independent manner. 
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CHAPTER 2 
TCR-INDEPENDENT SIGNAL 3 CYTOKINE CONTROL OF 
SECONDARY EFFECTOR CD4+ T CELL RESPONSES 
VIA IL-12, IFN-I, AND IL-10 
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Monoclonal memory CD4+ T cell populations are not functionally static, as the 
inflammatory environment can alter T cell function independent of TCR affinity. Two of 
the most prominent Signal 3 cytokines for CD8+ T cell activation, IL-12 and IFN-I, can 
also program CD4+ T cell responses during secondary challenge. IL-12 is required for IFNγ 
production and promotes the formation of highly functional secondary effector cells as 
measured by functional avidity. Conversely, IFN-I signaling inhibits secondary effector 
CD4+ T cell functional avidity, as well as diminishes IL-12 and IFNγ production. 
Interestingly, while IL-12 and IFN-I signaling are both requisite for the formation of 
primary memory CD4+ T cells after viral infection, secondary effector responses and 
subsequent memory formation do not require direct IL-12 or IFN-I during heterologous 
bacterial challenge. IFN-I can induce IL-10 in certain situations, and we observe that loss 
of IL-10 results in increased T cell functional avidity. However, changes in systemic 
inflammation induced by loss of IL-10 are different compared to loss of IFN-I signaling, 
implying that IL-10 and IFN-I influence T cell responses via distinct mechanisms. Overall, 
we show that IL-12 and IFN-I, acting as Signal 3 cytokines, differentially regulate IFNγ 
expression and secondary effector CD4+ T cell responses in a TCR and antigen-
independent manner. Additionally, we show that other cytokines may also have similar 
roles concerning T cell function, as IL-10 can influence these responses likely via different 




T cells are critical mediators of immunity, with both CD8+ cytotoxic T lymphocytes 
(CTLs) and CD4+ T helper cells performing crucial and indispensable roles in pathogen 
clearance. CD4+ T cells are particularly important, as they provide help to a variety of 
immune cell subsets including CTLs and B cells via stimulatory signals (1, 2). Upon initial 
activation, naïve CD4+ T cells differentiate into a variety of subsets, including T helper 1 
(Th1), Th2, Th17, and T regulatory cells (Treg) (3, 4). This initial differentiation requires 
three separate signals: antigen recognition, costimulation, and a third signal provided by 
soluble immune signaling molecules known as cytokines (5, 6). Signal 1, antigen 
recognition, occurs when antigen presented in the major histocompatibility complex 
(MHCII in the case of CD4+ T cells) is recognized by the T cell receptor (TCR). 
Costimulatory molecules on the T cell then recognize their counterpart on the antigen-
presenting cell (APC), providing the second signal. Finally, cytokine signaling induced by 
innate cells can signal to these CD4+ T cells and skew them to different T helper subsets 
(IL-12 promotes Th1 differentiation, etc.) (7). These cytokines are generally referred to as 
Signal 3 cytokines and have roles in both CD4+ and CD8+ T cell activation. While literature 
concerning their role in the primary differentiation of T helper cells is abundant, Signal 3 
cytokines in the context of secondary effector differentiation and function is less well 
defined. 
In the context of CD8+ T cells, two of the most studied Signal 3 cytokines are IL-
12 and Type I IFN family, comprised of 13 IFN-α genes and a single IFN-β in mice (8). 
Both cytokines have been shown to be necessary for the formation of robust antigen-
specific CD8+ T cell responses, with loss of either cytokine resulting in impaired responses 
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in a pathogen-dependent manner. During viral infections, IFN-I signaling has a dominant 
role as evidenced by decreased expansion of T cells lacking the IFN-α/β receptor (IFNAR) 
(9). IFN-I and IL-12 are both important for CD8+ T cell responses in immune responses to 
bacteria, as loss of signaling by either cytokine to CD8+ T cells during an infection to 
Listeria monocytogenes (Lm) reduces expansion, and loss of both cytokines in concert 
results in almost complete loss of expansion (10, 11). As with most biological rules there 
are exceptions to the pathogen-dependent role of these cytokines; for example, loss of IL-
12 during the CD8+ T cell priming phase of Chlamydia trachomatis infection actually 
improves the expansion and memory formation of these cells (12). The differences in the 
requirement of these cytokines is likely due to the distinct inflammatory environments 
formed during these different infections. We hypothesized that the inflammatory milieu 
could also augment secondary CD4+ effector responses, despite lineage commitment by 
previously differentiated primary memory cells. Differences in cytokine requirements for 
primary and secondary CD4+ T cell-mediated protection have been documented, 
supporting our hypothesis (13). 
 Previous work from our lab has shown that IL-12 and IFN-I differentially regulate 
secondary CD4+ T cell responses to Listeria infection (14). T cell sensitivity, a measure of 
T cell function, is calculated using functional avidity curves. Cells with high functional 
avidity are sensitive to low concentrations of peptide presented by MHC, while those with 
low functional avidity require higher peptide concentrations to induce a response. The 
effective concentration to elicit a half-maximal response of cytokine production (EC50), 
typically reported using IFNγ for both CD4+ and CD8+ T cells, is lower the higher the 
functional avidity. We observe that depletion of IL-12 reduces the functional avidity, 
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whereas blockade of IFN-I signaling increases the functional avidity of these T cells. This 
effect is independent of TCR affinity, as we observe this effect in a monoclonal population 
of memory cells. However, this effect is dependent upon the inflammatory environment, 
as differences in secondary effector T cell function are only observed after transfer to a 
naïve host prior to secondary challenge. We set forth to determine which changes to the 
overall inflammatory environment IL-12 neutralization and IFNAR blockade were 
producing, and how these changes mediate effects on T cell function. We show overall 
changes in levels of systemic IFNγ with either antibody treatment that are directly 
correlated to T cell function, in consensus with previously published work in Listeria 
infections (15–18). Additionally, we observe a complicated role for IFN-I signaling in 
CD4+ T cell expansion that appears to be phase-dependent, with IFN-I signaling being 
required during contraction to maintain the size of the secondary memory population, 
though it inhibits early IFNγ production. Utilizing knock-out mice, we also show that loss 
of IL-10, another cytokine important to Listeria infections (19–21), can increase T cell 
functional avidity. Overall, we observe that while secondary effector CD4+ T cells have 
already been programmed with their helper subset, they still require Signal 3 cytokine 
signaling to form optimal secondary effector responses and memory populations.  
 
Materials and Methods 
Mice and adoptive transfers 
Four to six week old C57Bl/6J mice were ordered from Jackson Laboratories (Bar 
Harbor, ME) for immediate use. Additionally, a small colony of these mice was maintained 
in our mouse facility at the University of Utah. Thy1.1+ SMARTA transgenic mice were 
bred and maintained in our mouse facility (22–24). CD45.1 (Ly5.1) mice were ordered 
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from Jackson laboratories (stock no. 002014) for use in adoptive transfer studies. 
SMARTA mice were bred to ifnγ-/- (stock no. 002287), il12rβ2-/- (stock no. 003248), and 
Ifnar-/- (stock no. 32045-JAX, kindly provided by Janis Weis from their colony at the 
University of Utah) to generate gene knock-out SMARTA mice for use in adoptive transfer 
experiments. Ifnar-/- and il10-/- (stock no. 002251) mice were also supplied by the Janis 
Weis lab for use as hosts in adoptive transfer studies (25). For adoptive transfers, untouched 
or memory CD4+ SMARTA cells were isolated from the spleens of naïve or memory mice, 
respectively, and isolated using MACS CD4+ T cell isolation kits, with the addition of 
biotinylated anti-CD44 for the isolation of untouched CD4+ T cells for a primary infection 
(14). One day prior to infection, 104 to 105 cells were injected intravenously (i.v.). 
 
Infections and antibody treatments 
LCMV-Armstrong and Lm-gp61 were stored and propagated as previously 
described (24). For primary infections with LCMV-Arm, mice were injected 
intraperitoneally (i.p.) with 2 x105 plaque forming units (PFU). For heterologous secondary 
infections with Lm-gp61, bacteria were first grown to log phase in BHI media as 
determined by the O.D. at 600 nm (0.3-0.7). Mice were then injected i.v. with 2x105 colony 
forming units (CFU), unless otherwise indicated. Primary infections with LCMV were 
done between 5-10 weeks of age, while primary and secondary infections with Lm-gp61 
were done 6 weeks later, when mice were 10-15 weeks old. All experiments using animals 
were performed under a protocol approved by the University of Utah IACUC (Protocol 
#15-09004, approved 9/23/2015). All antibody treatments were performed i.p. one day 
prior to infection. For anti-IL-12 antibody treatments, mice received a 0.5 mg injection of 
anti-IL-12 antibody (BioXCell, clone C17.8) one day prior to challenge, as previously. For 
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IFN-I blockade, mice received a 1.25 mg injection of anti-IFNAR1 antibody (BioXCell, 
clone MAR1-5A3) i.p. one day prior to infection as previous (14). 
Serum cytokine analysis 
Mice were bled on days 1 and 3 postchallenge. Blood was allowed to clot at room 
temperature then spun at max speed in a microcentrifuge for 20 minutes. Serum was 
collected and stored at -20C. Serum cytokine concentrations were measured using a custom 
6-plex LEGENDplex bead-based cytokine assay (Biolegend; IFNγ 740153, IL-1B 740157,
IL-6 740159, IL-10 740158, IL-12 (p70) 740156, TNF- 740154, Standard 740371, 
Detection antibodies 740165, buffer set B 740373) or a ProcartaPlex panel (eBioscience; 
IFNα and IFNβ panel EPX020-22187-901, custom panel for IL-18, IL-6, IFNγ, TNF, IL-
12p70, GM-CSF, IL-1β).  
Tissue and cell preparations 
Whole spleens and liver portions were collected in the tissue culture hood in 2 mL 
sterile PBS for clearance assays. Other tissue collections were done at the bench in 
nonsterile conditions. Livers were weighed, and all organs were dissociated using frosted 
microscope slides. For assessment of bacterial load, serial 1:10 dilutions were performed 
in sterile PBS and aliquots were plated on brain heart infusion agar (BHI) agar plates. Plates 
were incubated at 37C overnight. Colony counts were reported as CFU/spleen or CFU/g 
of liver. For all other cell preparations, dissociated tissues were places in single cell 
suspension in DMEM containing 10% fetal bovine serum (FBS), L-glutamine and 
Pen/Strep. For detection of intracellular cytokines, splenocytes were incubated with GP61-
80 peptide (GLKGPDIYKGVYQFKSVEFD) for 4 hours in the presence of Brefeldin A 
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(Golgi Plug), followed by fixation and permeabilization, according to the manufacturer’s 
instructions (BD Biosciences).  
Flow cytometry 
Cells were suspended in PBS + 1% FBS, then stained with fluorescent dye-
conjugated antibodies as indicated (Biolegend, San Diego, CA; BD Biosciences, San Jose, 
CA; eBioscience, San Diego, CA) for 20-40 minutes. Samples were collected on a 
LSRFortessa flow cytometer or FACSCanto (BD Biosciences) and analyzed using FlowJo 
(TreeStar).  
Statistical analysis 
Statistical significance was determined using the student’s t-test for two groups and 
ANOVA for more than two groups using GraphPad Prism 7 software. Graphs depict mean 
 SEM, with a p value of less than 0.05 being considered significant. p values are indicated 
as follows: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Results 
IFN-I and IL-12 differentially regulate systemic inflammation 
Our lab has previously produced data showing that, when transferred to naïve hosts 
prior to infection, secondary effector CD4+ T cell function can be augmented by 
manipulation of the IL-12 or IFN-I signaling pathways. To determine how disrupting these 
pathways influenced the systemic cytokine milieu, we adoptively transferred transgenic 
SMARTA CD4+ T cells to naïve WT B6 hosts and infected with LCMV. After memory 
formation, we performed a secondary adoptive transfer of these memory SMARTA cells 
to new, naïve hosts and then challenged with Listeria expressing the MHCII-restricted 
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GP61-80 epitope of LCMV (Lm-gp61). Cytokine pathways were disrupted with i.p. injection 
of neutralizing or blocking antibodies to IL-12 or IFNAR, respectively, 1 day prior to 
infection. As previously stated, we observe increased T cell functional avidity at day 7 
postchallenge in the absence of IFN-I, but a decrease in T cell function in the absence of 
IL-12 (14). This is only true when these signaling pathways are inhibited at the start of 
infection, as neutralization of either IL-12 or IFNAR signaling postinfection but prior to 
peak effector responses results in no difference when compared to T cells from PBS control 
animals (Chulwoo Kim, data not shown).  
To determine which early inflammatory signals might be controlling peak CD4+ T 
cell effector function, we examined changes to the systemic inflammatory environment 
caused by interruption of either IL-12 or IFN-I signaling 24 hours postchallenge with Lm-
gp61. We observed an increase in systemic IL-12p70 in the absence of IFN-I signaling, 
supporting previously published work (Fig. 2.1A). Additionally, we observe a similar 
increase in IFNγ in the absence of IFN-I. However, when IL-12 is neutralized, IFNγ levels 
are decreased, showing that IFNγ levels are controlled by IL-12 levels (Fig. 2.1B). This 
relative decrease in IFNγ is also observed when SMARTA cells are rechallenged in 
immune hosts, but the amount of total IFNγ is much higher, possibly explaining why we 
do not observe downstream effects on T cell function (data not shown). Similarly, we 
observe increased IL-6 in the absence of IFN-I signaling, though no change in IL-6 levels 
were observed in the absence of IL-12 signaling (Fig. 2.1C). IL-18 has been shown to 
synergize with IL-12 to induce IFN production in Th1 cells (26). However, while levels 
of IL-18 were increased with either antibody treatment, the lower limit of quantification 





Figure 2.1. IFN-I and IL-12 differentially regulate systemic inflammation. Serum 
cytokines were analyzed by ProcartaPlex kit for concentrations 1 day after infection. 
Striking differences were detected for IL-12p70 (A), IFNγ (B), and IL-6 (C). 
Nonsignificant or uninterpretable data were detected for IL-18 (D), TNF (E), IL-1β (F), 






































































































































































 (Fig. 2.1D). No other noteworthy differences in serum cytokines were observed in our 
selected cytokine panel (Fig. 2.1E, 2.1F, data not shown).  
Early TCR-independent signaling events control CD4+ secondary 
effector function 
As mentioned, we observe defects in T cell effector function at peak effector time 
points (day 7 postchallenge) in the absence of IL-12, while mice lacking IFN-I signaling 
produce more functionally adept effector cells. This corresponds to changes to IL-12 and 
IFNγ levels in the serum 1 day postchallenge. Levels of systemic inflammation throughout 
the first 7 days leading to peak effector response shows that the bulk of systemic 
inflammation occurs early after infection (IL-12, IFNγ, and IL-6), with levels dropping 
precipitously by day 3 and being nearly undetectable by day 5, days before the observed 
changes in T cell effector function (Fig. 2.2A-C). These levels drop regardless of antibody 
treatment or control treatment, demonstrating that changes to very early levels of these 
cytokines is sufficient to produce functional changes in secondary effector T cells in this 
heterologous secondary challenge model. Levels of TNF and IL-1β remain low in the 
serum throughout the effector response (Fig. 2.2D, E). IL-18 levels appear to remain high 
when either IL-12 or IFN-I signaling are disrupted, though again the high LLOQ results in 
data that is difficult to draw conclusions from (Fig. 2.2F).  
Another measure of T cell function is maintenance of T cells in the memory pool. 
It is well understood that the memory pool selects for highly functional T cells, so increased 
memory population size would indicate increased T cell function throughout the effector 
phase (27). We observe decreased expansion of secondary effector cells in the absence of 
IL-12, but a significant increase in expansion by day 7 postchallenge in the absence of   
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Figure 2.2. Early cytokine signaling controls secondary CD4+ T cell responses. (A-F) 
Serum collected as in Fig. 2.1 on various days postchallenge with Lm-gp61 were analyzed 
for systemic concentrations of various cytokines by ProcartaPlex. High levels are detected 
only at very early timepoints for IFNγ (A), IL-12p70 (B), and IL-6 (C). TNF (D), IL-1β 
(E), and IL-18 (F) levels showed no interesting patterns. (G) Numbers of Thy1.1+ 
SMARTA cells were calculated based on staining by flow cytometry and whole spleen 
numbers at days 8 and 56 postchallenge with Lm-gp61. Numbers reflect fold contraction 
between those timepoints. n=3 mice/group. Dotted lines indicate LLOQ. 
















































































































IFN-I. Contraction of secondary effector cells, measured as a fold decrease in the number 
of antigen-specific SMARTA  cells,  showed  a requirement  for  IFN-I  signaling  later  in 
infection, however. While the relative contraction was similar between control and anti-
IL-12 treated animals, regardless of peak effector population size, animals lacking early 
IFN-I signaling had substantially greater contraction to the memory population (Fig. 2.2G). 
This indicates an early programming of effector cells for retention in memory that is 
dependent on IFN-I signaling. This is interesting, as early initial expansion and effector 
function are benefitted in the absence of this signaling. This mirrors other work published 
on the role of IFN-I and IL-12 in CD8+ T cell function and expansion, where IFN-I in 
particular has a complicated role dependent on the phase of T cell response. 
 
T cells require direct IL-12 and IFN-I signaling to form memory after  
viral infection 
While treatment with anti-IL-12 and anti-IFNAR antibodies causes changes in T 
cell function, this does not indicate whether the role of these cytokines mediate these effects 
by directly signaling to T cells or inducing signaling cascades in other cells that 
subsequently induce changes in T cell function. To answer this question, we bred 
SMARTA mice deficient in either the IFN-I receptor IFNAR1 or the inducible IL-12Rβ2 
subunit of the IL-12 receptor. We initially established whether these cells could form 
primary memory, which is a critical component of the heterologous secondary challenge 
model. To test this, we cotransferred equal numbers of WT (Thy1.1+) and receptor knock-
out SMARTA (Thy1.1+Thy1.2+) cells into WT B6 hosts and challenged with LCMV. By 
8 days postchallenge, we saw defects in expansion of both receptor knock-out cell types 




Figure 2.3. T cells require IL-12 and IFN-I signaling to form memory after viral infection. 
Representative flow plots of CD4+ cells showing WT SMARTA (Thy1.1+) and receptor 
knock-out SMARTA (Thy1.1+Thy1.2+) cells transferred to a WT (Thy1.2+) host at days 8 
and 43 postchallenge with LCMV. 
 
staining (Fig. 2.3). This was greater in IFNAR1 knock-out SMARTA cells, as we could 
not detect these cells by day 8. Other groups have published similar data, evidencing a 
requirement for IFN- I signaling directly to Th1 primary effector cells during a viral 
infection (28). SMARTA cells lacking the IL-12Rβ2 subunit appear to be present at day 8 
postchallenge as measured by flow cytometry, but none of these cells are detectable in the 
memory population. This is not a surprising result, as IL-12 signaling is required for initial 
CD4+ T cell differentiation to the Th1 effector subset. Together, these data show that CD4+ 
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Th1 effector cells require both direct IL-12 and IFN-I signaling to properly respond to viral 
infections and form memory. Unfortunately, this renders these mice useless as tools to 
study the requirement of direct IL-12 and IFN-I signaling on T cells during a secondary 
effector response due to the lack of memory formation. 
 
Endogenous IFNγ expression by CD4+ effector cells is required for  
optimal response 
 For our previously published work examining the role of Signal 3 cytokines on T 
cell function, we show changes in functional avidity differentially mediated by IL-12 and 
IFN-I signaling. We were curious as to how critical this endogenous IFNγ production was 
for controlling overall T cell function, and to test this we bred IFNγ-deficient SMARTA 
cells (Thy1.1+Thy1.2+) for use in our heterologous secondary challenge model. Somewhat 
surprisingly, these cells were able to form a memory population that we could then 
cotransfer to naïve B6 hosts for heterologous secondary challenge with Lm-gp61. While 
initial adoptive transfer was performed at a 1:1 ratio between WT and ifnγ-/- SMARTA, by 
50 days postchallenge the memory population was skewed towards WT 3:1 (data not 
shown). We observe no defect in functional avidity in the absence of endogenous IFNγ 
production as measured by TNF at memory or secondary effector timepoints (Fig. 2.4A, 
data not shown). While somewhat surprising, due to these cells being Th1 secondary 
effector cells, this result can likely be explained by the presence of a large variety of other 
cells that produce IFNγ (e.g., WT SMARTA, endogenous CD4+ T cells, macrophages). 
We do however notice a significant decrease in the total numbers of SMARTA cells, and 
the number of these cells producing multiple cytokines (TNF+IL-2+) (Fig. 2.4B, C). The 
latter is an artifact of the total population size, as there are no differences in the proportion  
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Figure 2.4. CD4+ T cells require endogenous IFNγ production for maximum expansion. 
(A) WT and IFNγ-/- SMARTA cells in the same hosts were stimulated ex vivo with
decreasing concentrations of gp61-80 peptide and stained intracellularly for production of
TNF. Functional avidity curves were calculated, and the dotted line indicated the EC50. (B)
Total numbers of SMARTA cells in the spleen from each type were calculated using flow
cytometry staining and whole spleen counts. (C) Total numbers of TNF+IL-2+ SMARTA
cells were calculated using flow cytometry staining and the total numbers of SMARTA
cells. n=4 mice, cells were cotransferred into each mouse.
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of WT and ifnγ-/- SMARTA cells with multi-cytokine potential. These data support a role 
for IFNγ production in effective expansion of CD4+ effector T cells, potentially via an 
autocrine signaling pathway, though they also indicate that effector function is at least 
partially independent of endogenous IFNγ production. 
Loss of IFN-I signaling positively impacts T cell function in a 
T cell-indirect manner 
As previously mentioned, antibody-mediated IFNAR blockade experiments do not 
show if IFN-I is signaling directly to T cells to dampen T cell functionality. While Ifnar-/- 
SMARTA cells are not a viable option for our secondary challenge model (Fig. 2.3), we 
are able to address whether indirect loss of IFN-I signaling on all cell types except the 
SMARTA T cells is sufficient to induce changes in T cell function by using Ifnar-/- 
secondary hosts. To accomplish this, we adoptively transferred memory SMARTA cells as 
before, but this time using either WT controls or Ifnar-/- mice as secondary hosts, and 
subsequently heterologously challenged with Lm-gp61. It is important to note that, as with 
previous work with Listeria challenge of Ifnar-/- hosts, the pathogen is cleared more rapidly 
with the loss of IFN-I signaling (Fig. 2.5A). We also observe a similar increase in T cell 
functional avidity when all host cells lack IFNAR, indicating that these functional changes 
are produced via indirect signaling by IFN-I (Fig. 2.5B). Unlike with our IFNAR-blockade 
experiments, there are no significant differences in total numbers of SMARTA cells 7 days 
postinfection with the loss of IFN-I responsiveness in the host, indicating a partial role for 
IFN-I signaling directly to T cells that is specific to controlling cell expansion (Fig. 2.5C). 
The fact that these hosts more rapidly clear pathogen could be complicating the 
interpretation of these results, as the memory pool is populated by T cells with higher  
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Figure 2.5. Effects of IFN-I are CD4+ T cell-indirect and antigen-independent. Memory 
SMARTA cells from LCMV-immune mice were transferred to naïve WT or Ifnar-/- hosts 
and infected with Lm-gp61. (A) Bacterial burden at 3 days postchallenge were measured 
by CFU of Lm-gp61 per spleen. (B) The functional avidity as measured by IFNγ production 
by SMARTA cells in responses to ex vivo stimulation with decreasing concentrations of 
gp61-80 peptide. (C) The number of SMARTA cells in the spleen as calculated from flow 
cytometry staining and total splenocyte numbers at day 7 postchallenge. (D) Bacterial 
burden 3 days postchallenge with Lm-gp61 at the initial infectious dose indicated. (E) The 
functional avidity of the SMARTA population in response to different infectious doses, as 
noted in the figure, reported as the EC50. (F) Effector population size at day 7 postchallenge. 
(G) Proportion of IFNγ-producing SMARTA cells that are also able to make TNF and IL-



































functional avidity and faster clearance may correlate to more rapid formation of the 
memory population (14, 23, 27, 29). To rectify this, we increased the infectious dose to 
produce similar levels of bacterial in the spleen as the WT host 3 days postchallenge. While 
10-fold increase of the infectious dose in an Ifnar-/- host still results in significantly fewer 
bacteria in the spleen by day 3 postchallenge compared to a WT animal, the difference 
between clearance in WT and Ifnar-/- animals is smaller than when both genotypes are 
given equivalent doses (Fig. 2.5D). Importantly, changing early the bacterial burden in the 
spleen has no effect on later T cell functional avidity, as the EC50 at day 7 postchallenge is 
effectively identical regardless of infectious dose in the Ifnar-/- host (Fig. 2.5E). Similarly, 
infectious dose has no significant effect on the number of SMARTA secondary effector 
cells (Fig. 2.5F). Both infectious doses result in increased proportions of IFNγ-producing 
cells also producing TNF and IL-2 compared to SMARTA cells in WT hosts, but increasing 
the infectious dose does not induce a difference when compared to the lower dose (Fig. 
2.5G). Taken together, we have shown a T cell indirect and antigen-independent role for 
IFN-I signaling in controlling the extent of CD4+ effector responses during a heterologous 
Listeria challenge. 
Challenge of Ifnar-/- mice results in a distinct inflammatory profile 
 With use of neutralizing and blocking antibodies, as in Figures 2.1 and 2.2, we 
expected and observed broad changes to the cytokine milieu. Similarly, challenge of     
Ifnar-/- hosts with lm-gp61 should induce an altered inflammatory state due to the lack of 
productive IFN-I signaling in most cells. We observe that WT mice actually have higher 
serum levels of IFNγ 1 day postchallenge (Fig. 2.6A). This is the opposite of what we 




Figure 2.6. Systemic inflammation in WT and Ifnar-/- animals after Lm-gp61 challenge. 
Serum was obtained on days 1 and 3 postchallenge and analyzed via LegendPlex multiplex 







signaling to CD4+ T cells. Specifically, it appears that IFN-I may reduce T cell production 
of IFNγ through IFNAR on the T cells themselves. While this is sufficient to reduce 
systemic levels of IFNγ early in infection, we still observe functional changes to T cells in 
these hosts at later timepoints.  As with IFNAR-blockade, we do observe an increase in  
IL-12 levels by day 1 postchallenge when Ifnar-/- hosts are infected with a normal or high 
infectious dose (Fig. 2.6B). While the higher infectious dose does result in lower levels of 
IL-12 compared to the normal infectious dose, this difference is not significant and it is 
still higher than in WT animals. While none of the other cytokines observed showed truly 
significant differences when all groups were compared (Fig. 2.6C-E), IL-10 did show a 
confusing profile. When Ifnar-/- hosts were infected with comparable levels of bacteria as 
WT hosts, there was a significant increase in IL-10, but not when they were infected with 
10-fold more bacteria (Fig. 2.6F). While these results are statistically significant, we fail to 
draw any real conclusions from this due to the large error range and low number of mice 
per group. Repetition of this experiment will show if this is accurate or just an artifact due 
to an outlier animal.  
 
Loss of IL-10 exerts similar effects on T cell function as loss of  
IFN-I signaling 
 As previously mentioned, one of the downstream effects of IFN-I signaling is the 
induction of IL-10 (30–32). IL-10, produced by Tregs and innate cells such as 
macrophages, is a potent antiinflammatory molecule that can mediate downregulation of 
proinflammatory cytokines such as IFNγ and IL-12. We hypothesized that one way IFN-I 
signaling may impede the formation of secondary effector cells with high functional avidity 
was via induction of IL-10, a cytokine known to inhibit production of IL-12. To test this, 
43 
we repeated earlier adoptive transfer experiments, but this time using il10-/- hosts rather 
than Ifnar-/- hosts. Similar to what we observe in Ifnar-/- animals and consistent with 
previously published work, il10-/- animals clear Listeria infections more rapidly (Fig. 
2.7A). SMARTA cells in il10-/- animals exhibited increased functional avidity but no 
significant differences in expansion by day 7 postchallenge (Fig. 2.7B, C), but as with 
challenge in Ifnar-/- hosts this could be due to more rapid clearance and contraction to 
memory populations. To rectify this, we again increased the infectious dose by 10-fold and 
examined whether these changes to T cell function were independent of the bacterial load 
(i.e., antigen-independent). Increasing the initial infectious dose results in day 3 bacterial 
loads in the spleen similar to those of WT animals infected with the normal infectious dose 
(Fig. 2.7D). Interestingly, while the clearance is approximately the same between normally 
and highly infected il10-/- mice, there in a further significant increase in functional avidity 
of these cells, compared to both WT and il10-/- animals infected with normal bacteria (Fig. 
2.7E). As this is an initial study, repetition of this experiment will be required to determine 
if this is an antigen-dependent increase in effector function or just a slight difference due 
to low group numbers. While there could be an antigen-dependent effect on the functional 
avidity of these cells, there is no difference in expansion due to differences in bacterial 
burden (Fig. 2.7F). 
IL-10 and IFN-I have different effects on systemic inflammation 
We examined serum cytokine concentrations during early response to Lm-gp61 
challenge and, while there are some similarities to the cytokine profile produced by 
challenge of Ifnar-/- mice, the overall systemic cytokine milieu is distinct for the il10-/- and 
Ifnar-/- hosts (Fig. 2.8). Specifically, IFNγ levels are similarly lowered in il10-/- hosts 
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Figure 2.7. Loss of IL-10 exerts similar effects on T cell function as loss of IFN-I signaling. 
Memory SMARTA cells were transferred to naïve WT or il10-/- hosts and infected with 
Lm-gp61. (A) Bacterial burden at 3 days postchallenge were measured by CFU of Lm-
gp61 per spleen. (B) The functional avidity as measured by IFNγ production by SMARTA 
cells in responses to ex vivo stimulation with decreasing concentrations of gp61-80 peptide. 
(C) The number of SMARTA cells in the spleen as calculated from flow cytometry staining
and total splenocyte numbers at day 7 postchallenge. (D) Bacterial burden 3 days
postchallenge at the initial infectious dose indicated. (E) The functional avidity of the
SMARTA population in response to different infectious doses, as noted in the figure,




Figure 2.8. Systemic inflammation in WT and il10-/- animals after Lm-gp61 challenge. 
Serum was obtained on days 1 and 3 postchallenge and analyzed via LegendPlex multiplex 
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compared to WT animals (Fig. 2.8A). Other similarities include no significant differences 
in IL-1β, IL-6, and day 1 levels of TNF (Fig. 2.8B-D). Day 3 levels of TNF are elevated in 
the absence of IL-10, which is most likely due to the lack of antiinflammatory signaling 
due to a lack of Treg function (Fig. 2.8D). As expected, IL-10 levels are lower in il10-/-  
animals, but there are detectable levels of this cytokine even in the knock-out animals (Fig. 
2.8E).   This  is  either   due  to  the   presence  of  SMARTA   cells  and  the  plasticity  of 
differentiated T helper cells to produce cytokines not typically attributed to their 
differentiated helper subset (33, 34), or potentially due to nonspecific binding in the 
detection assay. Surprisingly, IL-12 levels were not affected by the absence of IL-10 
signaling (Fig. 2.8F). This indicates that IFN-I signaling in our model is likely not 
influencing IL-12 levels via IL-10 induction, as we would expect an equivalent increase in 
IL-12 in both genotypes if that were the case. Ultimately, this serum data indicate that IL-
10 and IFN-I utilize different mechanisms to regulate T cell function, though there may be 
some overlap.  
 
Discussion 
 The role of Signal 3 cytokines in CD8+ T cell function is well-described, 
particularly concerning IL-12 and IFN-I. As with much of the T cell canon, the emphasis 
of study typically falls on CTLs, rather than CD4+ T helper cells, leaving the role of Signal3 
cytokines during secondary effector CD4+ responses poorly understood. Here we used a 
TCR transgenic mouse model to study the role of TCR-independent cytokine signaling in 
programming secondary effector CD4+ T cell function. We observe two different but 
potentially related mechanisms of controlling these responses, via either IFN-I signaling or 
IL-10 signaling. IFN-I inhibits IL-12 production, which in turn decreases overall IFNγ 
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production and T cell effector function. Inhibition of this pathway via receptor inhibition 
or knock-out results in increased early systemic IL-12 and IFNγ, as well as increased T cell 
effector function. IL-10, on the other hand, does not appear to impact IL-12 levels, but 
reduced IL-10 levels increase T cell function. Overall, we observe a significant role for 
Signal 3 cytokines in the secondary effector differentiation of memory CD4+ T helper cells 
that is independent of their TCR affinity for antigen.  
 Further study is required to understand how these and other Signal 3 cytokines will 
influence T cell responses in different infectious settings. Here we use a Listeria infection 
model, but it is well appreciated that different types of infections can induce different 
cytokine signaling. As mentioned, IFN-I signaling is detrimental for protection from 
bacterial infections such as Listeria but is required for protection in a viral setting. 
However, we are currently unsure of the role of IFN-I on T cell function in a viral setting, 
particularly in regards to secondary effector differentiation. We observe that primary 
effector CD4+ T cells fail to properly expand and form memory in response to challenge 
with LCMV when they lack IFNAR1, indicating a requirement for direct IFN-I signaling 
to CD4+ T cells during primary viral infection that is consistent with published data 
concerning CD8+ T cells. To study the role in a secondary viral infection, we must use 
different experimental tools, specifically a different heterologous secondary challenge 
model. Primary infection with Lm-gp61 fails to produce a robust primary memory 
population, so simply inverting the order in which we use LCMV and Lm-gp61 will not be 
sufficient for these studies. Our lab has a strain of vaccinia virus that also expresses gp61-
80 (VV-gp61), meaning we can use this virus in place of Lm-gp61 in our heterologous 
rechallenge model to study the role of Signal 3 cytokines in memory CD4+ T cell-mediated 
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secondary responses to a virus. Regardless of which tools are used, it is clear that further 
study is required to determine whether the role of IFN-I signaling in regards to T cell 
function is dependent upon the infection. 
 Additional questions remain based on the data we have presented here. First, it is 
likely that Ifnar-/- and il10-/- do not have the same bacterial burden throughout infection 
compared to WT animals, even with increased infectious doses, due to differences in their 
kinetics of clearance. Examining the bacterial burden and T cell functional avidity 
maturation throughout the entire response to acute infection will determine if T cell 
functional differences are truly an antigen-independent effect of IFN-I and IL-10 signaling. 
Additionally, augmenting the clearance of WT animals via antibiotics such as ampicillin 
would demonstrate whether or not increased clearance rates are contributing to our 
observed phenotype. Second, the cytokine concentrations observed at the systemic level 
may not accurately represent the inflammatory environment at the site of infection, in this 
case the spleen and to a lesser extent the liver. More targeted analysis at the site of infection 
through qRT-PCR would give a more accurate representation of the cytokine milieu that is 
surrounding the T cells in question. Many other questions can be raised based on the data 
presented here to further our understanding of Signal 3 cytokines in this context, but these 
proposed follow-up studies will help to cement or reshape the conclusions we have drawn 
thus far. Increased comprehension of the roles of IFN-I, IL-12, and IL-10, along with other 
cytokines, in secondary T cell differentiation and subsequent memory formation will 
provide much-needed information in bolstering and augmenting vaccination and adjuvant 
therapies. Our studies will specifically provide information that can be utilized in the 
development of secondary vaccination or booster strategies. 
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In this dissertation, we explore cytokine-mediated control of CD4+ T cell responses. 
We observe a TCR-independent role for cytokine signaling in determining the strength of 
the recall response for CD4+ T cells. Furthermore, the requirement for individual cytokines 
is determined by the invading pathogen, as evidenced by differential requirements for 
specific cytokines in the immune response to either viral or bacterial pathogens. Our work 
has defined the requirement for a variety of pro and antiinflammatory cytokines during 
secondary challenge with Listeria monocytogenes, a facultative intracellular bacterium, 
when protection is mediated by CD4+ T helper cells. We illustrate the roles of multiple 
cytokines induce by infection with Listeria and how these molecules control CD4+ T cell 
secondary effector responses (Fig. 4.1).  
In Chapter 2, we explore the roles of the two most well-studied Signal 3 cytokines: 
IL-12 and type I interferons (IFN-I’s). We show that, as with CD8+ T cells, these cytokines 
can produce effects on the function of T helper cells. Loss of IL-12 signaling leads to 
reduced expansion and decreased functional avidity of secondary effector CD4+ T cells, 
even in a monoclonal TCR population such as SMARTA CD4+ T cells (1). Overall, we 
conclude that IL-12 induction of IFN correlates to CD4+ T cell functional avidity and 
expansion during an acute bacterial infection. It is important to note that the differences in 
effector function caused by interruption of IL-12 signaling only occur when LCMV- 
immune memory cells are transferred to a naïve mouse. While there is a proportional 
decrease in circulating IFNγ when naïve or LCMV-immune mice are treated with IL-12 
neutralizing antibodies, the level of IFNγ is still much higher in the immune mouse than 
the baseline in the naïve mouse. 




Figure 4.1. Visual summary of signal 3 cytokine signaling during secondary CD4+ T cell 
responses described in this dissertation. IL-12 production can be inhibited by IFN-I and 
IL-10, which results in changes to T cells. Additionally, IFN-I can directly influence T cell 
responses specifically concerning expansion kinetics. Additionally, TNF produced by T 
cells and, possibly to a lesser extent, macrophages, is critical for bacterial clearance. IFN, 
while critical for protection in primary responses to Listeria, proves to be expendable for 
early protection during a CD4+ T cell-mediated secondary response. Large dashed lines 
indicate mechanisms inferred based on the current literature. 







by Listeria infection curtailed secondary CD4+ T cell effector responses, as blockade of 
the IFN-I receptor (IFNAR) produced secondary effector CD4+ T cells with significantly 
higher functional avidity. This corresponded to a large increase in circulating IL-12 and 
IFNγ in the absence of IFN-I signaling, supporting the role of both of these cytokines in 
productive effector responses. Use of knock-out animals allowed us to study the role of 
IFN-I on secondary T cell responses in a more targeted way. We determined that this effect 
was T cell-indirect, as when all cells except for the T cells lacked IFNAR we still observed 
increased functional avidity. This effect appears to be independent of antigen as well as 
TCR, as a similar increase in functional avidity is observed at normal and 10-fold higher 
than normal infectious doses of Listeria.  
However, IFN-I may play a direct role in expansion kinetics of secondary effector 
CD4+ T cells, as differences in expansion and contraction are observed only when IFNAR 
signaling on T cells is disrupted. While loss of IFNAR signaling on T cells leads to more 
robust expansion of secondary effector cells, a greater degree of contraction is observed 
during secondary memory formation. Blocking antibodies to IFNAR were only given once 
directly prior to infection, but the duration of antibody binding to receptor is not defined 
and was not investigated. Future work on this subject should verify the duration of the 
blockade to better describe the role of this pathway. If the blockade persists for the duration 
of the acute response, it would indicate a beneficial requirement for IFN-I to minimize the 
contraction phase. Others have shown that IFN-I can in fact extend the presentation of the 
IL-2Rα on the surface of CD8+ T cells to prevent contraction, which may likely be 
important for CD4+ T cells as well. As expansion is greater in the absence of early IFN-I 
signaling, there could alternatively be an increased differentiation to the short-lived 
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effector cell (SLEC) subset, leading to greater cell death after pathogen clearance (2). 
Analysis for SLEC versus memory-precursor effector cell (MPEC) markers such as 
KLRG1 and CD127, as well as IL-2Rα (CD25), will determine whether IFN-I is important 
for controlling the early differentiation of effector cells. 
Work by others indicated a potential pathway of immune evasion induced by 
Listeria, wherein IFN-I’s signal to macrophages to induce IL-10 production, which 
subsequently decreases macrophage-produced IL-12 (3). Use of il10-/- mice in place of 
ifnar-/- mice produces a significant but smaller increase in functional avidity. More 
importantly, there is no change in circulating IL-12 levels in the absence of IL-10 compared 
to WT hosts, a stark contrast to the significant increase observed in ifnar-/- mice. These 
data, as well as differences in the number of CD4+ T cells with multicytokinic potential, 
indicate that while both IL-10 and IFN-I control secondary CD4+ T cell effector responses, 
they do so to different degrees and through different mechanisms during Listeria infection. 
In Chapter 3, we show that CD4+ memory T cells are able to confer protection from 
secondary heterologous challenge, but that this is entirely dependent upon TNF signaling. 
Importantly, this illustrates one of the many distinctions between primary and CD4+ T cell-
mediated secondary protection to Listeria. While IFN is generally considered to be the 
most important cytokine for primary protection, we observe that it is TNF and not IFN 
that is of particular importance during the secondary response. Additionally, TNF is also 
important for a primary response, but TNF-dependent protection is not identical between 
primary and secondary infections. In a primary infection, there is a loss of protection 
leading to a significant increase in CFU compared to control treated animals. During a 
secondary infection with CD4+ memory T cell-mediated protection, the CFU are reduced 
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to around naïve levels, not higher. Additionally, previous work indicates that neutralization 
of TNF during a primary infection leads to death of all mice by day 4 postinfection (4). We 
observe very little mortality after neutralization of TNF in the presence of CD4+ memory 
T cells during a secondary heterologous challenge (data not shown), indicating that though 
CD4+ T cell-mediated protection requires TNF, overall survival may not be as dependent 
upon TNF in immune mice. Alternatively, incomplete neutralization may allow for survival 
of these animals, and thus repeating these experiments with increased application of TNF-
neutralizing antibodies will determine if survival during heterologous secondary challenge 
is also dependent upon TNF.  
Both Chapters 2 and 3 indicate that IFNγ is important during the immune response 
to Listeria, though there appears to be a complicated role for this cytokine in secondary 
effector CD4+ T cell responses. In Chapter 2, we observe what appears to be a positive 
correlation between effector function and circulating IFNγ levels. This appears to be 
confirmed in Chapter 3, as increased protection also correlates to elevated levels of 
circulating IFNγ. However, neutralization of IFNγ does not result in a severe defect in 
protection as would be expected based on previous publications (5–7). Additionally, 
neutralization of TNF does not result in a change in circulating IFNγ. While this may 
indicate that IFNγ is effectively dispensable for CD4+ T cell-mediated protection from 
secondary challenge, we do observe that neutralization of TNF reduces the expression of 
the IFNγ receptor on macrophages. This implies IFNγ has at least a minor role in protection 
from secondary challenge, at least in the macrophage compartment. The focus of this 
chapter was on the very early response to Listeria, ending with analysis at day 3. We have 
studied this neutralization over a longer time course just once and do not observe any 
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significant differences in clearance throughout the acute infection. Other work has 
indicated that perhaps loss of protection may not be observable by day 3 postinfection (8), 
so future exploration of this with a specific focus on the latter phase of the acute response 
will determine if our observation holds true for the duration of the immune response or if 
there is in fact a defect in later clearance in the absence of IFNγ.  
Together, the data presented here show that Signal 3 cytokines control effector T 
cell responses in a TCR and possibly antigen-independent manner, and that it is possible 
to manipulate the cytokine milieu in such as a way as to produce more effective secondary 
effector T cell responses. Beyond simple effects on individual cells, we observe differences 
in protection when cytokine signaling is interrupted. Importantly, the roles of these 
cytokines are dependent on the pathogen, as many have reported differences between the 
roles of IL-12 and IFN-I’s in viral and bacterial infections. This dissertation focuses 
exclusively on infections with Listeria, but our lab does possess a strain of vaccinia virus 
expressing the MHCII-restricted epitope of LCMV GP61-80 (VV-gp61) much like the strain 
of Listeria used in the work presented here (Lm-gp61). Future studies implementing a VV-
gp61 secondary challenge could be used to determine what role the cytokines presented 
here play in CD4+ T cell-mediated protection from secondary viral infection. We would 
expect an opposite role for IFN-I’s during a viral infection as has been extensively 
published, but IL-12, TNF, and IFNγ in particular could have similar roles on CD4+ T cell 
function in both viral and bacterial settings, though whether this translates to controlling 
the protective effect of these memory cells is another matter. 
In addition to ascertaining the role of Signal 3 cytokines during CD4+ T cell-
mediated protection in a viral setting, many questions remain regarding the mechanisms 
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by which TNF and other cytokines control memory CD4+ T cell-mediated protection. For 
example, we have published data describing a protective role for CD4+ T cells but have yet 
to fully determine what factors mediate that protective effect. We have shown that 
protection is dependent upon TNF, rather than IFN, but observe no significant differences 
in TNF expression between naïve and LCMV-immune mice infected with Lm-gp61. Study 
of cytokine signaling at the site of infection, in this case the spleen, will likely provide 
more insightful data to illustrate a mechanism for CD4+ T cell-mediated protection. 
Techniques such as RNA-sequencing or more targeted quantitative PCR will allow us to 
analyze gene expression patterns with and without the presence of LCMV-immune CD4+ 
memory T cells specifically at the site of infection. This will allow us to observe whether 
there is in fact an increase in TNF in the spleen that is not reflected by systemic cytokine 
concentrations. Additionally, it will allow us to better determine what other cytokines are 
important in regards to memory CD4+ T cell-mediated protection, such as IL-18 (9). 
Importantly, a 7-day time course should be examined as cytokine signaling is not static 
throughout infection. Analysis of individual cell populations such as T cells and 
macrophages can then be performed using flow cytometry and qPCR to examine 
phenotypic differences in these cells that are affected by the different inflammatory 
environments. Markers could include the IL-2R, which has been correlated to decreased 
contraction, or markers for SLECs and MPECs to determine the fate of effector T cells.  
Our attempts to determine whether IFN-I and IL-12 are required to signal directly 
to T cells during secondary effector responses have so far failed due to the tools available 
to us. Fortunately, there are tools available to study this, though they are not currently cost-
effective. The Knockout Mouse Program has an IL12Rb2 floxed mouse that, in conjunction 
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with an inducible cre driver under the CD4 promoter, would result in T cells that can have 
the IL12 receptor specifically deleted after primary memory formation. However, the 
floxed mouse is only available via cryo recovery as of yet and therefore is a prohibitive 
expense for that experiment. While studying IL-12 signaling to T cells continues to be 
problematic based on the available tools, there is now an IFNAR floxed mouse available 
through Jackson Laboratories that could be of use to further test our hypothesis that IFN-I 
is required to minimize contraction during secondary memory formation. Additionally, this 
would allow for deletion of the receptor not just after primary memory formation, but at 
any time during the secondary response to determine at what stage IFN-I programming of 
the contraction phase occurs.  
Subsequent work will be required to determine if IL-12 and IFN-I play a role in 
CD4+ T cell-mediated protection. As mentioned, differences in effector function caused by 
disruption of IL-12 or IFN-I signaling are only observed in naïve hosts, which is likely due 
to the high concentrations of IFN in LCMV-immune hosts. Even though this is the case, 
it would be interesting to examine the effects of IL-12 neutralization or IFNAR blockade 
during heterologous challenge of LCMV-immune hosts without any adoptive cell transfer. 
This will also allow for direct comparison to the TNF and IFN neutralization experiments, 
and study without secondary transfer will more accurately determine if there is any 
biological significance to the potential for these cytokines to program secondary CD4+ T 
cell responses. Importantly, early attempts at determining what role of IL-12 and IFN-I 
play in protection were inconclusive. It is therefore important to elucidate this fact through 
neutralization of IL-12 or IFNAR blockade in our heterologous rechallenge model. We 
have additionally hypothesized, based on previous work by our lab and others, that more 
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robust secondary responses programmed by optimal Signal 3 cytokine signaling lead to 
better memory formation. We have examined memory only after secondary adoptive 
transfer, which may not be completely biologically accurate. Determining the role that all 
of these cytokines play in secondary memory formation will indicate whether there are 
long-term effects on CD4+ T cells that are programmed by early Signal 3 cytokine 
signaling.  
As mentioned, our published work concerning TNF and IFN in CD4+ T cell-
mediated protection focus primarily on the early protection and signaling events. We have 
yet to explore the effects that depletion of these cytokines have on secondary memory 
formation, such as the contraction phase and memory maintenance. While we would expect 
that stronger effector responses would correlate with more rapid clearance, and 
subsequently more robust memory formation, this may not be the case. Specifically, while 
TNF depletion results in slower clearance and we would therefore expect greater 
contraction to memory or poor maintenance of secondary memory, IFN may not follow 
those same principles. As Th1 can be activated by IFN signaling as well as IL-12, there 
may be some effects on the secondary memory population that do not present as a defect 
in protection. Additionally, we have yet to determine the effect blocking these signaling 
pathways have on the functional avidity of the secondary effector population. Subsequent 
study in this area should start here, as it will help to complete the story we have started to 
tell concerning the role of TNF and IFN in controlling CD+ T cell-mediated protection. 
Finally, future studies should examine the potential of direct cell killing by 
secondary effector CD4+ T cells. Since protection is mediated by these cells, it is possible 
that secondary effector Th1 cells also have cytolytic potential that leads to their directly 
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killing infected cells, resulting in the more rapid clearance of pathogen that we observe. 
Cytolytic CD4+ T cells have been recently described, with similar granzyme B and perforin 
cell-killing mechanisms as CD8+ CTLs (10–14). Additionally, CD4+ CTLs utilize the Fas-
FasL pathway to mediate cell killing. Future use of intracellular and surface staining for 
granzyme B, perforin, and FasL will help to define the potential cytolytic phenotype of 
these memory CD4+ T cells. Furthermore, in vivo cell killing assays can be employed to 
directly examine the cell-killing function of these cells. Though mechanisms regulating the 
programming of these cytolytic functions are not identical to those determining 
differentiation to the Th1 subset, it is generally held that CD4+ CTLs are typically Th1 
cells. Memory CD4+ T cells with cytolytic capacity could be acting as both coordinators 
of the immune response as well as direct mediators of cell killing. Therefore, determining 
what impact Signal 3 cytokines have on CD4+ T cell-mediated cytotoxicity via in vivo 
assay will indicate whether CD4+ memory T cell-mediated protection is via immune 
coordination alone or whether they have a more direct protective role. 
While the data presented here focuses on T cell function in a nontranslational 
manner, there are important implications for understanding the inflammatory cues that can 
influence T cell responses.  Importantly, the development of vaccines and immunotherapies 
require an advanced understanding of mechanisms regulating productive immune 
responses and long-lived immune memory. We have previously touched on the broadly 
immunoregulatory function of CD4+ T cells, and thus the memory population generated 
should include CD4+ T cell memory. By understanding how the inflammatory milieu 
interacts with T cells during the response to acute infection or vaccination, it is 
subsequently possible to adjust said milieu via adjuvant therapies such as the addition of 
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recombinant cytokines or neutralization of other cytokines (15–17). In fact, mouse studies 
have been performed utilizing a mutant form of TNF as an adjuvant in both vaccinations 
for HIV and cancer therapies (18–20). It is this potential for use in cancer immunotherapies 
that is particularly interesting, as the importance of CD4+ T cells in the antitumor response 
has become more appreciated as of late (21, 22). The work presented in this dissertation 
explores just a few of the multitude of cytokines with potential regulatory roles in CD4+ T 
cell effector function, but this work provides an important initial understanding as to the 
ideal inflammatory environment for the generation of optimal effector CD4+ T cells that 
may later be applied to the development of immunotherapeutics. Similarly, our lab has 
collaborated with a number of clinicians to examine how immune profiles are altered 
during the course of treatment for metastatic melanoma. We are particularly interested in 
determining if there are any specific markers, such as elevated levels of specific cytokines 
in the serum, which correlate either to response to therapy or continued progression of 
disease. While much of this work is ongoing and has yet to be published, the following 
Appendix gives one example of this correlative work. Ongoing and future work relating to 
these projects will further explore the potential for these potential diagnostics. 
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